Evolus Inc. shares extended their recent decline in Tuesday’s session, closing at $7.58 after shedding 0.92% of their value. Trading activity saw the stock fluctuate within a $7.42 to $7.70 range, representing a 3.76% spread, while volume decreased by 211,000 shares to settle at 658,000 for the day.
Institutional Activity and Insider Trading
Despite the bearish price action, institutional investors demonstrated continued interest in the aesthetics company. Russell Investments Group Ltd. boosted its stake by 5.4% during the first quarter of 2025, acquiring an additional 6,015 shares to bring its total holdings to 118,085 shares valued at approximately $1.42 million. Vanguard Group Inc. similarly increased its position by 2.0%, now controlling 3.23 million shares. In a more significant move, Nuveen LLC established a completely new position worth $12.33 million.
Insider transactions presented a more divided picture. Chief Marketing Officer Tomoko Yamagishi-Dressler disposed of 5,722 shares at $7.51 per share on August 22, while Director Brady Stewart purchased 30,000 shares at $6.82 on August 15.
Quarterly Performance: Revenue Growth Masks Profitability Challenges
The company’s second quarter 2025 financial results revealed both strengths and weaknesses. Evolus reported global net revenue of $69.4 million, representing a 4% year-over-year increase driven by the successful launch of Evolysse™ filler products and robust international performance.
Should investors sell immediately? Or is it worth buying Evolus?
Beneath the surface of these revenue gains, however, significant profitability challenges emerged. The company’s GAAP operating loss expanded to $10.2 million, worsening from the $7.7 million loss recorded during the same period last year. Even on an adjusted non-GAAP basis, the company reported a $7.9 million loss—a stark contrast to the adjusted profit of $1.1 million achieved in the second quarter of 2024.
Future Outlook and Strategic Initiatives
Management reaffirmed its full-year 2025 guidance, projecting net revenue between $295 million and $305 million, which would represent growth of 11% to 15%. The company anticipates achieving meaningful profitability by the fourth quarter of 2025 and targets annual profitability beginning in 2026.
This path to profitability is expected to be supported by cost reduction measures aimed at saving at least $25 million in adjusted operating expenses. Evolus maintains ambitious long-term targets, including reaching $700 million in total revenue and achieving a 20% non-GAAP operating profit margin by 2028.
Product Pipeline Developments
On August 20, Evolus submitted its Evolysse™ Sculpt filler for FDA approval. This product candidate, which targets mid-face volume loss, represents a significant expansion of the company’s product portfolio. Positive study data for the filler were previously presented at the Cosmetic Bootcamp conference. The FDA decision is anticipated during the second half of 2026.
- Recent Trading: Shares declined 0.92% to $7.58 on August 27
- Institutional Support: Russell Investments increased holdings by 5.4% in Q1 2025
- Revenue Performance: Q2 sales grew 4% to $69.4 million
- Profitability Target: Meaningful profitability expected from Q4 2025
- Regulatory Progress: FDA submission for Evolysse™ Sculpt completed August 20
Ad
Evolus Stock: Buy or Sell?! New Evolus Analysis from January 13 delivers the answer:
The latest Evolus figures speak for themselves: Urgent action needed for Evolus investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 13.
Evolus: Buy or sell? Read more here...
